Biogen Idec Inc., Elan Corporation, Chevron Corporation, CNOOC Ltd., and
ExxonMobil Corporation highlighted in Zacks Analyst Blog
CHICAGO, Jan. 18, 2013
CHICAGO, Jan. 18, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Biogen Idec Inc. (BIIB), Elan
Corporation (ELN), Chevron Corporation (CVX), CNOOC Ltd. (CEO) and ExxonMobil
Today, Zacks is promoting Four daily picks are offered free.
Here are highlights from Friday's Analyst Blog:
Biogen, Elan Seek Label Expansion
Biogen Idec Inc. (BIIB) and partner Elan Corporation (ELN) recently submitted
applications to the US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) seeking to update the label of their multiple sclerosis
(MS) drugTysabri (natalizumab).
The companies are looking to get Tysabri approved as a first line treatment
for patients suffering from certain relapsing forms of multiple sclerosis (MS)
who have tested negative for antibodies to the JC virus (JCV).
The application is based on risk stratification data. Tysabri slows disability
progression by 42% – 54% and reduces annualized relapse rates by 68%.
Tysabri is the primary growth driver at Elan. As per Elan, Tysabri global net
sales in the third quarter of 2012 rose 9.8% to $306.4 million. However, third
quarter 2012 Tysabri revenues at Biogen declined 1% to $275 million.
We note that Tysabri is approved in the US for treating relapsing forms of
multiple sclerosis (MS) in patients who show inadequate response to or are
unable to tolerate other treatments. In the EU, Tysabri is approved for
treating highly active relapsing-remitting MS (RRMS) in adults who have severe
RRMS or have not responded to beta interferon treatment.
In the EU, Tysabri was approved in 2006 and in the US it was initially
approved in 2004. The product was withdrawn from US markets in 2005 due to the
progressive multifocal leukoencephalopathy (PML) concern. The drug was
reintroduced by Biogen and Elan after a year with a strict warning regarding
the occurrence of PML.
We currently have a Neutral recommendation on both Biogen and Elan. While
Biogen carries a Zacks Rank #3 (Hold) in the short run, Elan carries a Zacks
Rank #2 (Buy).
Chevron to Explore in China
Chevron China Energy Company – subsidiary of the U.S. energy behemoth Chevron
Corporation (CVX) – entered into two production sharing agreements with China
National Offshore Oil Corporation – parent company of the Chinese energy giant
CNOOC Ltd. (CEO).
The contracts are for the exploration of blocks 15/10 and 15/28 located in
Xijiang Sag of Pearl River Mouth Basin in the eastern part of the South China
Sea. Together, the blocks cover an area of about 2,233 square miles in water
depth of 50–100 meters.
Per the deals, Chevron will have 100% stake in both the shallow water blocks,
while CNOOC will have the right to share up to 51% in any commercial
discovery. Chevron will operate both the blocks and will carry out 3D seismic
data surveys. The cost of the same will be borne by Chevron. No other
financial term was disclosed.
This deal is a part of the strategic move by Chevron to develop its business
in the Asia Pacific region.
Chevron is currently a Zacks Rank #3 (Hold) stock, implying that it is
expected to perform in line with the broader U.S. equity market over the next
one to three months. We are also maintaining our long-term Neutral
recommendation on the stock.
The energy giant's current oil and gas development project pipeline is among
the best in the industry, boasting large and multi-year projects.
Additionally, this second-largest U.S. oil company by market value after
ExxonMobil Corporation (XOM) possesses one of the healthiest balance sheets
among its peers that help it to capitalize on strategic investment
However, due to its integrated nature, Chevron is particularly susceptible to
the downside risk from any weakness in the global economy. We are also
concerned about the company's high level of capital spending, which may result
in reduced returns going forward.
Today, Zacks is promoting Four daily picks are offered free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is `being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.